法匹拉韦联合干扰素对比洛匹那韦/利托那韦联合干扰素治疗中度COVID-19的随机对照试验方案
该试验为在伊朗Shahid Mohammadi医院开展的3期、单中心、随机、开放标签、平行对照试验,计划纳入60例年龄≥20岁、确诊SARS-CoV-2感染且需住院的中度COVID-19肺炎患者,按1:1区组随机分配至法匹拉韦联合干扰素β-1a组或洛匹那韦/利托那韦联合干扰素β-1a组。主要结局为随机化后7天鼻咽拭子SARS-CoV-2病毒载量(RT-PCR)以及发热和氧饱和度的临床改善。
要点
- 试验比较法匹拉韦联合干扰素β-1a与洛匹那韦/利托那韦联合干扰素β-1a在中度COVID-19患者中的疗效与安全性
- 主要结局为随机化后7天病毒载量及发热、氧饱和度的临床改善
- 计划纳入60例患者,按1:1区组随机分配,每组30例
核心结论
- 该方案旨在评估法匹拉韦联合干扰素β-1a对比洛匹那韦/利托那韦联合干扰素β-1a在中度COVID-19患者中的疗效与安全性。
研究设计与样本
- 3期、单中心、随机、开放标签、平行对照试验,在伊朗Shahid Mohammadi医院开展。
- 计划纳入60例年龄≥20岁、确诊SARS-CoV-2感染、中度COVID-19肺炎且住院≤48小时的患者。
- 采用区组随机(每区组10例)按1:1比例分配,每组30例。
关键数值与推荐
- 干预组:法匹拉韦首日1600 mg每日两次,随后4天600 mg每日两次;联合干扰素β-1a 44 mcg隔日一次共5剂。
- 对照组:洛匹那韦/利托那韦200/50 mg每日两次共7天;联合干扰素β-1a 44 mcg隔日一次共5剂。
- 主要结局:随机化后7天鼻咽拭子SARS-CoV-2病毒载量(RT-PCR)及发热和氧饱和度临床改善。
- 次要结局:随机化后7天住院时长和严重药物不良反应发生率。
局限性
- 开放标签设计,无盲法和安慰剂对照。
- 单中心、样本量较小(计划60例),可能影响结果外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We will evaluate the efficacy and safety of favipiravir and interferon beta-1a compared to lopinavir/ritonavir and interferon beta-1a in patients with confirmed COVID-19, who are moderately ill. TRIAL DESIGN: This is a phase 3, single-center, randomized, open-label, controlled trial with a parallel-group design carried out at Shahid Mohammadi Hospital, Bandar Abbas, Iran. PARTICIPANTS: All patients with age ≥ 20 years admitted at the Severe Acute Respiratory Syndrome Departments of the Shahid Mohammadi Hospital, Bandar Abbas, Iran, will be screened for the following criteria. INCLUSION CRITERIA: 1. Confirmed diagnosis of infection with SARS-CoV-2 using polymerase chain reaction and/or antibody tests. 2. Moderate COVID-19 pneumonia (via computed tomography and/or X-ray imaging), requiring hospitalization. 3. Hospitalized ≤ 48 h. 4. Signing informed consent and willingness of the participant to accept randomization to any assigned treatment arm. EXCLUSION CRITERIA: 1. Underlying conditions, including chronic hepatitis, cirrhosis, cholestatic liver diseases, cholecystitis, peptic ulcers, acute and chronic renal failure, and peptic ulcers. 2. Severe and critical COVID-19 pneumonia. 3. History of allergy to favipiravir, lopinavir/ritonavir, and interferon beta-1a. 4. Pregnancy and breastfeeding. INTERVENTION AND COMPARATOR: Intervention group: favipiravir (Zhejiang Hisun, China) with interferon beta-1a (CinnaGen, Iran). This group will receive 1600 mg favipiravir twice a day for the first day and 600 mg twice a day for the following 4 days with five doses of 44 mcg interferon beta-1a every other day. CONTROL GROUP: lopinavir/ritonavir (Heterd Company, India) with interferon beta-1a (CinnaGen, Iran). This group will receive 200/50 mg lopinavir/ritonavir twice a day for 7 days with five doses of 44 mcg interferon beta-1a every other day. Other supportive and routine care will be the same in both groups. MAIN OUTCOMES: The primary outcome of the trial is the viral load of SARS-CoV-2 in the nasopharyngeal samples assessed by RT-PCR after 7 days of randomization as well as clinical improvement of fever and O2 saturation within 7 days of randomization. The secondary outcomes are the length of hospital stay and the incidence of serious adverse drug reactions within 7 days of randomization. RANDOMIZATION: Eligible patients will be allocated to one of the study arms using block randomization in a 1:1 ratio (each block consists of 10 patients). A web-based system will be used to generate random numbers for the allocation sequence. Each number relates to one of the study arms. BLINDING (MASKING): This is an open-label trial without blinding and placebo control. NUMBERS TO BE RANDOMIZED (SAMPLE SIZE): A total of 60 patients will be randomized into two groups (30 patients in the intervention group and 30 patients in the control group). TRIAL STATUS: The trial protocol is version 1.0, 22 July 2020. Recruitment began on 25 July 2020 and is anticipated to be completed by 25 September 2020. TRIAL REGISTRATION: Iranian Registry of Clinical Trials (IRCT) IRCT20200506047323N3 . Registered on 22 July 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting the dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol.
引用
- Hassaniazad M, Bazram A, Hassanipour S, et al. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials. 2020. PMID: 33109246. doi:10.1186/s13063-020-04747-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。